tldrdailynews.com logo

Merck's Oral PCSK9 Inhibitor Shows Promising Results in Phase 3 Trials

1 min read
Source: Business Wire
Merck's Oral PCSK9 Inhibitor Shows Promising Results in Phase 3 Trials
Photo: Business Wire
TL;DR

Merck announced positive topline results from two Phase 3 trials of enlicitide decanoate, an oral PCSK9 inhibitor, showing significant LDL-C reductions in adults with hyperlipidemia, with no major safety concerns, potentially making it the first oral PCSK9 inhibitor if approved.

Topics:businesshealthcare#enlicitide#healthcare#hyperlipidemia#ldl-c-reduction#merck#phase-3-trials
Share this article
  1. Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia  Business Wire
  2. Merck's potential blockbuster cholesterol pill succeeds in late-stage studies  Reuters
  3. Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials  Fierce Biotech
  4. Merck & Co.'s oral PCSK9 inhibitor succeeds in dual Phase III trials  FirstWord Pharma
  5. Merck Pill Lowers Cholesterol Levels. By How Much Is the Critical Point.  Barron's

Want the full story? Read the original reporting

Read on Business Wire